MedCity News November 12, 2024
Neurogene’s Rett syndrome gene therapy has preliminary data supporting safety and efficacy of the one-time treatment. But a late-breaking report of a serious complication in a patient who received the high dose sent shares of the biotech downward.
A Neurogene gene therapy in development for the rare neurodevelopmental disorder Rett syndrome has encouraging early data in a small group of patients, an interim readout that comes a week after a private placement infused the biotech with $200 million to last it the next two years. But investors are focusing on a late-breaking development — a complication experienced by a patient who received the high dose of the experimental one-time treatment.
The data reported after Monday’s market close are from seven...
Today's Sponsors
Today's Sponsor